XenoGesis to attend EBF Barcelona

XenoGesis to attend EBF Barcelona
November 9, 2017 suecarr

XenoGesis will be attending EBF in Barcelona for the 10th Open Meeting, which takes place on the 15th – 17th November 2017.

EBF was founded in 2006 at the initiative of 12 pharmaceutical companies, all of them having bioanalytical lab activities in Europe. The goal of bringing these companies together was to implement a platform for discussions of science, day-to-day procedures, business tools, technologies and last but not least regulatory issues. EBF is open to European companies and CROs involved in bioanalytical activities in a pharmaceutical research and development environment, including  in Europe.

XenoGesis will be presenting two posters at the meeting:

1. The Use of a Q EXACTIVE ORBITRAP for Enhanced In Vitro DMPK Support

The high resolution capability of the Q-Exactive makes it the instrument of choice for metabolite identification utilising various MS/MS modes eg. AIF, vDIA & PRM for generating product ion spectra. It is now also proving ideal for in vitro assays such as hepatocytes, microsomes and blood stability without the requirement for an MRM optimisation.

The Q-Exactive’s fullscan sensitivity allows for rapid quantitative analysis of various in vitro stability assays and where instability is identified, can determine the metabolic products from the same analytical run.

This poster aims to highlight the flexibility and capability of the Q-Exactive for supporting the extensive range of in vitro DMPK assays offered by XenoGesis requiring fast turnaround analysis.

2. The combined use of the TSQ Quantiva and Q-Exactive for Quantitative PK Bioanalysis

Traditionally bioanalysis is the domain of triple quadrupole instruments while high resolution, accurate mass instruments are used for qualitative analysis such as metabolite identification. A triple quad will usually be the instrument of choice for maximum sensitivity. However, using high resolution instruments can provide the selectivity and specificity that selected reaction monitoring (SRM) on a triple provides. This offers an alternative bioanalytical approach where absolute sensitivity isn’t required, such as in vitro screening assays, or where compounds are problematic on a triple for various reasons. Using high resolution instruments for bioanalysis in a  Discovery DMPK environment is complementary to the strengths of a triple quad and provides a wider scope for solving problems.


Last year XenoGesis opened its new state-of-the-art Bioanalysis Suite, following the investment in the latest liquid chromatography-mass spectrometry (LC-MS) equipment to enhance its bioanalysis and metabolic identification capabilities.


For more information on the event, click here.